Minocycline for Chronic Autoimmune Uveitis
Minocycline for Chronic Autoimmune Uveitis
Recruiting
Phase 1
Phase 2
Interventional Study
Minocycline
Uveitis
Retinal Degeneration
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 – 70
- Sex
- Any
- Trial phase
- Phase 1/2
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 10 (estimated)
- Sponsor
- Sun Yat-sen University · Other
Who this trial is looking for
This trial is looking for adults with autoimmune diseases that have caused vision problems. If you join, you will take minocycline and attend regular visits to check your progress.
Are You a Good Fit for This Trial?
You may be able to join if
- I have been diagnosed with an autoimmune disease that has affected my vision.
- I am between 18 and 60 years old.
- I can sign the informed consent document.
- I am able to attend the required visits.
You may not be able to join if
- I am allergic to minocycline or tetracyclines.
- I have a problem with my liver, heart, kidneys, or thyroid.
- I am currently taking glucocorticoids, immunosuppressants, or biologics.
- I am pregnant, breastfeeding, or planning to become pregnant.
- I am taking other medications for other diseases.
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Autoimmune uveitis is one kind of non-infectious, sight-threatening, relapsing and severe ocular disease. Approximately 20%-25% autoimmune uveitis patients suffer from the dilemma of blindness for the chronic and persistent inflammatory state in the eyes, which results in continuous destroy in the structure of the eyes and gradually leads to irreversible damage on visual function. However, it show…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Participant diagnosed of autoimmune diseases with visual function damage (decrease of BCVA, loss of retinal structure)
* Participant aged from 18-60 years old.
* Participant that signed the informed consent document and is able to complete the following visits.
Exclusion Crit…
Contacts